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Abstract
BACKGROUND: Cetuximab, a monoclonal antibody targeting the Epidermal
Growth Factor Receptor (EGFR), has demonstrated activity in various tumor
types. Using dynamic contrast-enhanced computed tomography (DCE-CT), we
investigated the early activity of cetuximab monotherapy in previously untreated
patients with squamous cell carcinoma of the head and neck (SCCHN).
METHODS: Treatment-naïve patients with SCCHN received cetuximab for 2
weeks before curative surgery. Treatment activity was evaluated by DCE-CT at
baseline and before surgery. Tumor vascular and interstitial characteristics were
evaluated using the Brix two-compartment kinetic model. Modifications of the
perfusion parameters (blood flow Fp, extravascular space ve, vascular space
vp, and transfer constant PS) were assessed between both time points. DCE
data were compared to FDG-PET and histopathological examination obtained
simultaneously. Plasmatic vascular markers were investigated at different time
points. RESULTS: Fourteen...
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Background. Cetuximab, a monoclonal antibody targeting the Epidermal Growth Factor Receptor (EGFR), has 
demonstrated activity in various tumor types. Using dynamic contrast-enhanced computed tomography (DCE-CT), 
we investigated the early activity of cetuximab monotherapy in previously untreated patients with squamous cell 
carcinoma of the head and neck (SCCHN).
Methods. Treatment-naïve patients with SCCHN received cetuximab for 2 weeks before curative surgery. Treatment 
activity was evaluated by DCE-CT at baseline and before surgery. Tumor vascular and interstitial characteristics were 
evaluated using the Brix two-compartment kinetic model. Modifications of the perfusion parameters (blood flow Fp, 
extravascular space ve, vascular space vp, and transfer constant PS) were assessed between both time points. DCE 
data were compared to FDG-PET and histopathological examination obtained simultaneously. Plasmatic vascular 
markers were investigated at different time points.
Results. Fourteen patients had evaluable DCE-CT parameters at both time points. A significant increase in the ex-
travascular extracellular space ve accessible to the tracer was observed but no significant differences were found for 
the other kinetic parameters (Fp, vp or PS). Significant correlations were found between DCE parameters and the other 
two modalities. Plasmatic VEGF, PDGF-BB and IL-8 decreased as early as 2 hours after cetuximab infusion. 
Conclusions. Early activity of cetuximab on tumor interstitial characteristics was detected by DCE-CT. Modifications 
of plasmatic vascular markers are not sufficient to confirm anti-angiogenic cetuximab activity in vivo. Further investi-
gation is warranted to determine to what extent DCE-CT parameters are modified and to evaluate whether they are 
able to predict treatment outcome.
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Introduction
The Epidermal Growth Factor Receptor (EGFR) is 
overexpressed in up to 90% of all squamous cell 
carcinomas of the head and neck (SCCHN) 1, and 
EGFR overexpression is linked with poor progno-
sis.2,3 The EGFR is a member of the HER tyrosine 
kinase receptor family composed of four different 
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receptors (EGFR/c-erbB-1, c-erbB-2/HER-2/neu, 
c-erbB-3/HER-3, and c-erbB4/HER-4), all of which 
are transmembrane proteins with tyrosine kinase 
activity.4 The EGFR has an extracellular domain 
which provides a ligand-binding site. Upon ligand 
fixation, EGFR homodimerization or heterodimi-
zation with another HER receptor occurs leading 
to activation of the intracellular tyrosine kinase. 
This stimulates kinase signal transduction path-
ways involved in tumor proliferation, inhibition 
of apoptosis, angiogenesis and cell migration/inva-
sion. Downstream signaling through the Ras/Raf/
Mek/Erk pathway controls cell proliferation and 
cell cycle progression, while the phosphatidylino-
sitol-3-kinase/protein kinase B (PI3K/Akt) pathway 
stimulates numerous antiapoptotic signals.
Cetuximab, a chimeric IgG1 monoclonal an-
tibody (mAb) that specifically binds to the EGFR 
with high affinity, has been approved in combi-
nation with radiotherapy for locally advanced 
SCCHN and in combination with platinum based 
chemotherapy for recurrent and/or metastatic 
SCCHN.5-7 However the objective response rate 
in monotherapy remains low at between 10% and 
13%.8 Postulated mechanisms of action of cetuxi-
mab include (i) downregulation of the EGFR and 
its downstream molecular signaling pathways by 
competing with EGFR natural ligands like EGF 
or TGF-alpha, (ii) antibody-dependent cell-medi-
ated cytotoxicity (ADCC) through the activation 
of macrophages and natural killer cells, and (iii) 
inhibition of DNA double strand-break repair.9-12 
Furthermore decreased secretion of vascular li-
gands like VEGF-A, IL-8 and FGF-2 has been de-
scribed by other investigators(13,14), leading to the 
hypothesis that beside a direct effect on tumour 
cell proliferation, cetuximab could also induce 
anti-angiogenic effects and thereby influence in-
directly tumor progression. Other investigators 
showed vascular normalization associated with 
increased vessel density and blood flow after anti-
EGFR treatment in xenograft models.15,16
Dynamic Contrast-Enhanced Computed 
Tomography (DCE-CT) is now recognized as a 
useful non-invasive imaging tool to investigate 
vascular and interstitial tumor characteristics.17-19 
In SCCHN, DCE-CT has been used to study blood 
volume, blood flow, permeability, tumor neoan-
giogenesis, and consecutive intratumoral arterio-
venous shunts.20-22 These observations have been 
confirmed in several studies22-25 and were correlat-
ed with intratumoral microvessel density (MVD)26, 
and with pathological aggressiveness and an-
giogenic markers such as vascular endothelial 
growth factor.27-29 Several investigators have also 
used DCE-CT to try to establish predictive mark-
ers of treatment response after induction chemo-
therapy or radio-chemotherapy in patients with 
SCCHN.20,21,30
We therefore implemented this technique in 
a pre-operative window opportunity study in 
SCCHN, in which cetuximab activity was inves-
tigated.31 Cetuximab monotherapy was adminis-
tered for two weeks prior to surgery to treatment-
naïve patients selected for primary surgical treat-
ment. 2-[fluorine-18]-fluoro-2-deoxy-D-glucose 
positron emission tomography (18FDG-PET) and 
imaging, including DCE-CT, were performed at 
baseline and before surgery. It has been shown 
that 18FDG-PET and DCE-CT are complementary 
imaging techniques for surveillance assessment 
in patients with SCCHN and that their combina-
tion may improve tumor outcome prediction. 32 In 
this paper, we report on the effect of cetuximab 
monotherapy to modify the vascular and intersti-
tial characteristics of SCCHN tumors as assessed 
by DCE-CT.
Patients and methods
Thirty-three treatment naïve patients with oper-
able SCCHN were enrolled into a monocentric 
window pre-operative study between August 2008 
and February 2011.31 In the first part of the study 
(N = 12 patients), safety of the concept was evalu-
ated by progressive reduction of the delay between 
the last cetuximab administration and surgery. In 
the expansion part of the study (N = 20 patients), 
all patients were treated with a loading dose of 
400 mg/m2 of cetuximab on day -15 before surgery 
followed by 250mg/m2 on days -8 and -1 before 
FIGURE 1. Schematic view of the study protocol.
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surgery (day 0) (Figure 1). Details of the eligibility 
criteria, 18FDG-PET responses of the whole group, 
biology and safety have been published.31 The clin-
ical and translational parts of the study were ap-
proved by the Independent Ethics Committee and 
the Belgian Health Authorities and conducted in ac-
cordance with the Declaration of Helsinki (October 
2000). Written informed consent was obtained for 
each patient. It was prospectively planned to per-
form translational research and patients gave their 
informed consent for repeated imaging.
Perfusion imaging
DCE-CT scans were performed on the 20 patients 
treated in the expansion part of the study at two 
time points: before the first cetuximab infusion and 
strictly two hours after the third dose. Imaging 
used a 16-detector row CT scanner (Philips Medical 
Systems, Best, the Netherlands). Acquisition pa-
rameters were: tube voltage 90 kVp; reference tube 
current-time product 200 mAs, temporal resolu-
tion 1 s, total scan time 120 s, number of slices 4, 
in-plane spatial resolution 0.68x0.68 mm, slice 
thickness 6 mm, image matrix size 512x512. Raw 
data were reconstructed by using a FBP algorithm. 
PET-CT fusion was used to locate the lesions on CT 
images.
The software Image J (processing program de-
veloped by the National Institutes of Health, http://
rsbweb.nih.gov/ij/) was used to segment the re-
gions of interest (ROI). An expert head and neck 
radiologist manually drew the ROI which included 
the internal carotid (for the arterial input function 
calculation) and the whole tumor (Figure 2).
Time intensity curves (TICs) were analyzed 
according to the Brix two-compartment kinetic 
model (Figure 2).33 This model relies on four pa-
rameters: blood flow Fp (mL.s-1.g-1); fraction of 
extravascular extracellular space accessible to the 
contrast agent ve (%); fraction of vascular space 
vp (%); and the transfer constant PS (mL.s-1.g-1), 
which depends on the permeability and surface 
area for transendothelial exchanges of the capillary 
wall. An additional free parameter τ (s), to account 
for the contrast agent bolus arrival time in the tis-
sues of interest, was included. As a result, the final 
expression of the kinetic model was:
Ctissue (t) = Fp.Cplasma (t-τ)  Rtissue (t) [1]
where Cplasma(t-τ) is the TIC in the feeding artery 
and Rtissue(t) is the impulse response function of the 
tissue taken the form:
Rtissue (t) = A.e-αt + (1-A).e-βt
vp = Fp / [ A.(α - β) + β ]
PS = [ α + β -  αβ / (A.(α - β) + β) ].vp [2]
ve = PS / [ αβ / (A.(α - β) + β) ]
The model was fitted to the TICs using a trust 
region algorithm.34 Multiple start values for the 
free parameters were explored in an attempt to 
find the solution corresponding to the true global 
minimum of the error function. All parameters 
were constrained to be positive. The sum (ve + vp) 
was constrained to be less than 1. No upper bound-
ary was imposed on Fp or PS. To obtain the coeffi-
cients Fp and PS in mL.min-1.100g-1, the coefficients 
expressed in mL.s-1.g-1 were multiplied by 60 s min-1 
and by 100. Cetuximab-induced changes in the 
A
B
FIGURE 2. Example of time intensity curves derived from the internal carotid and 
tumoral lesion before (A) and during treatment with cetuximab (B) in a patient with 
a squamous cell carcinoma of the head and neck. The quality of the fits of TICs 
using the Brix two-compartment kinetic model was found to be good (estimation of 
the root mean squared error of the regression averaged on the 14 normalized fits: 
εpre-treatment = 5%, εduring-treatment = 6%).
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pharmacokinetic parameters Fp, ve, vp and PS were 
then investigated.
18FDG-PET imaging
All patients underwent two 18FDG-PET/CT assess-
ments on a Philips 16-slice GEMINI TF camera 
(Philips Healthcare, The Nederlands): a baseline 
PET at the time of inclusion and an evaluation 
18FDG-PET aimed at estimating the residual tumor 
metabolic activity at the end of the cetuximab regi-
men (performed strictly 2 hours after the final infu-
sion of cetuximab and one day before surgery).
As a surrogate of tumor metabolic activity, the 
maximal standardized FDG uptake value (SUVmax) 
was recorded at each time point within the entire 
tumor volume using 3D volumes of interest (VOIs) 
and calculated using the following formula:
SUVmax = maximal pixel value * weight / 
corrected injected dose * 1000 [3]
with SUVmax in g.mL-1, maximal pixel value in 
Bq.mL-1, weight in kg, and the dose in Bq. To reflect 
the modification in tumor metabolism induced by 
the treatment between two PET studies, the param-
eter ∆SUVmax (in %) was defined using the follow-
ing formula:
∆SUVmax = [ (SUVmaxE-PET - SUVmaxB-PET) / 
SUVmaxB-PET) ] * 100 [4]
Based on published EORTC criteria  for solid tu-
mor evaluation with PET35, tumor metabolism was 
considered to be progressive (non responding to 
treatment) if ∆SUVmax was > 25% between the two 
PET studies; stable for ∆SUVmax between -25% and 
+25%; partially responding for ∆SUVmax ≤ -25%, 
and in complete metabolic response in case of non 
residual uptake. The PET-CTs were centrally re-
viewed by the same person.
Tumor cellularity
Residual tumor cellularity was determined on he-
matoxylin and eosin-stained (HE) slides including 
the whole tumor as previously described.31 Stained 
slides were digitized by a slide scanner (Mirax 
Scan; Zeiss, Jena, Germany). The surface composed 
of tumor cells only and the surface of the whole 
tumor were manually drawn by the same inves-
tigator (SS) who was blinded to the DCE-CT and 
18FDG-PET results. Tumor cellularity (expressed as 
a %) was the surface occupied by tumor cells divid-
ed by the surface of the whole tumor that included 
tumor cells, inflammatory cells, normal interstitial 
tissue and areas with morphologic signs of thera-
py-induced regression such as fibrosis and scaring.
Plasma analyses
Plasma samples (3 ml) were collected at several 
time points: (T1) at baseline before any cetuximab 
infusion; (T2a) before the last dose of cetuximab 
(day -1 before surgery); (T2b) 2 hours after the last 
dose of cetuximab; (T3) before surgery after intuba-
tion; and (T4) 5 weeks after surgery.
Vascular endothelial growth factor (VEGF), 
fibroblast growth factor (FGF)-basic, platelet de-
rived growth factor (PDGF)-BB and interleukin 
(IL)-8 plasma levels were quantified using the Bio-
Rad multiplex bead immunoassay (Luminex). The 
assay was performed in a 96 well plate format and 
analysed with the Luminex200 instrument (BIO-
RAD), which monitors the spectral properties of 
the capture beads while simultaneously measuring 
the quantity of associated fluorophore.
Statistical analysis
Numerical variables were expressed as mean ± 
standard deviation. DCE-CT parameters, 18FDG-
PET parameters, tumor cellularity and Luminex re-
sults were compared before and during treatment 
using the non-parametric Wilcoxon rank-sum test. 
A non-parametric test was chosen as the normal-
ity of the data distribution was not verified (on the 
basis of the D’agostino-Pearson test). Correlations 
between parameters were assessed based on 
Spearman’s rank coefficient. All calculations were 
done with Matlab (Matlab R2011b, MathWorks, 
Natick, MA, USA). A p-value < 0.05 was regarded 
as statistically significant for all tests cited above.
 
Results
Study population
Twenty patients were included in the expansion 
part and treated with three doses of cetuximab. 
DCE-CT images were spatially registered with a 
rigid transformation in order to compensate for 
patient motions.36 However, in four patients out 
of 20, displacement or deformation of the oral cav-
ity during the perfusion sequence was too severe 
to be corrected. In two additional patients, dental 
artifacts prevented from measuring the first pass of 
the contrast agent in the ROI with a high signal to 
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TABLE 1. Quantitative imaging parameters from DCE-CT and 18FDG-PET before and during treatment with cetuximab in 14 patients 
with squamous cell carcinoma of the head and neck 
Patient
Fp ve* vp PS SUV* Cellularity Tumor
(mL.min-1.100g-1) (%) (%) (mL.min-1.100g-1)  (%) localization, staging
Pretreatment
1 313.7 30.3 8.1 53.8 14.3 - L, T2N0
2 378.6 39.2 12.0 59.7 16.8 - OC, T2N0
3 157.2 15.4 16.0 37.7 10.6 - OC, T2N0
4 366.5 60.5 13.7 81.9 11.4 - OC, T1N0
5 73.9 41.8 15.3 28.6 9.9 - OC, T1N0
6 136.1 30.9 11.1 69.2 13.4 - OC,T4N0
7 278.0 36.4 15.5 47.3 8.8 - L, T2N0
8 116.9 39.5 13.6 42.0 8.3 - OC, T2N1
9 93.7 41.9 13.0 82.9 16.2 - OC, T2N1
10 163.2 21.9 9.5 37.2 12.3 - L, T2N0
11 72.7 29.1 9.2 38.1 7.4 - OC, T2N0
12 286.6 49.8 5.6 40.9 28.9 - OC, T3N0
13*** 128.0 37.0 10.8 44.6 14.8 - OC, T2N0
14 222.8 21.1 18.7 36.2 18.9 - OC, T2N2b
m ± SD 199 ± 107
35 ± 
12
12 ±
 3.5
50 ± 
17
14 ± 
5.6 -
Post treatment
1 281.1 30.3 9.0 42.6 9.2 77
2 292.6 47.9 8.5 87.4 8.4 45
3 305.9 40.1 11.8 45.6 4.8 38
4 357.9 66.7 14.5 75.0 4.9 34
5 40.8 46.1 8.6 31.4 11.4 55
6 99.1 18.0 4.5 78.3 6.8 40
7 219.6 38.7 2.2 40.4 4.5 54
8 411.9 53.3 3.9 60.5 4.9 49
9 72.4 68.4 31.2 30.7 4.3 25
10 92.3 53.5 12.8 22.8 6.7 63
11 75.9 77.6 14.6 44.1 3.9 35
12 184.0 47.4 8.9 33.8 3.4 22
13*** 131.2 46.1 9.9 60.7 6.0 26
14 359.2 33.7 13.7 53.7 8.3 36
m ± SD 209 ± 126
48 ± 
16
11 ± 
7.0
51 ± 
20
6.3 ± 
2.3
42.8± 
15.5
* Parameters with significant statistical differences between pretreatment and during treatment (p < 0.05)
*** PET/CT, Diffusion-weighted MR images and TICs are given in Figures 4 and 2.
Fp = blood flow; ve = extracellular, extravascular fraction; vp = fraction of vascular space; PS = transfer constant, L = larynx; OC = oral cavity
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noise ratio. As a result, 14 patients out of the origi-
nal 20 qualified at both imaging time points for a 
quantitative assessment of the tumoral perfusion. 
Eleven and three patients had SCC of the oral cav-
ity and larynx, respectively.
Anatomic imaging
Nine out of the 14 patients had measurable lesions 
according to response evaluation criteria in solid 
tumor (RECIST) version 1.1. The largest diameter 
of the tumor decreased by more than 30% in only 
one patient. Other patients had stable disease (SD) 
according to RECIST criteria.
Functional imaging and tumor cellularity
Quantitative imaging parameters are summarized 
in Table 1. A significant difference between pre-
treatment and during cetuximab treatment was 
observed for the extravascular extracellular space 
ve (p = 0.0085). Other kinetic parameters were not 
found to differ significantly (Fp: p = 0.5416; vp: p = 
0.2958; PS: p = 0.5830).
Among the 14 patients, all except one had a 
partial response (PR) according to the 18FDG-PET 
EORTC guidelines. Only one patient had an in-
crease in SUVmax between the two 18FDG-PET scans 
(ΔSUVmax + 15%). For the other patients, ΔSUVmax 
was between -25% and -50% for 7 patients and be-
low -50% for 6 patients.
We have previously shown that cetuximab de-
creased tumor cellularity in  resected specimens 
compared to untreated patients.31 Analysis of tu-
mor cellularity in HE slides of resected tumor 
specimens showed a median cellularity of 43% 
[range: 22% - 77%]. Tumor cellularity was more 
pronounced for the 3 larynx carcinomas [range: 
54% - 77%] than in the 11 tongue carcinomas 
[range: 22% - 51%]. Ten out of the 14 patients (71%) 
had a tumor cellularity < 50%. 
A significant though moderate inverse correla-
tion between the extravascular extracellular space 
ve and SUVmax (ρ = -0.40, p = 0.03) was observed. No 
other correlation was observed between DCE-CT 
parameters and 18FDG-PET parameters and tumor 
cellularity, or between the delta values of the re-
spective parameters. A significantly strong corre-
lation was found between cellularity and ∆SUVmax 
(ρ = 0.84, p = 0.0003) in these 14 patients. 
Plasma analysis
VEGF, FGF-basic, PDGF-BB and IL-8 plasmatic 
levels decreased as early as 2 hours (T2b) after ce-
tuximab perfusion. At the moment of surgery, the 
plasmatic levels of all these ligands were signifi-
cantly upregulate (Figure 3).
Discussion
The main purpose of this study was to investigate, 
using DCE-CT, the ability of cetuximab mono-
therapy to modify a tumor’s vascular and intersti-
tial characteristics. Cetuximab is known to block 
EGFR-dependent intracellular downstream mo-
lecular pathways.
In our model, a significant increase in the ex-
travascular extracellular space ve between pretreat-
ment and during treatment was observed. In addi-
tion to the modification of ve, a 18FDG-PET partial 
response according to EORTC criteria and tumor 
cellularity inferior to 50% in the resected specimens 
were observed in 90% and 71% of the 14 reported 
patients, respectively.
Modifications on blood flow Fp, vascular space 
vp or transendothelial exchanges PS could not be 
demonstrated. Since most of our patients did not 
experience tumor shrinkage, our results suggest 
that cetuximab induces modifications in tumor 
composition reflected by reduced metabolic tu-
mor activity (∆SUVmax) and increased peritumoral 
space, as shown by an increase in ve and a decrease 
in tumor cellularity. These modifications are con-
FIGURE 3. Modifications of VEGF, FGF-basic, IL-8 and PDGF-BB plasmatic levels 
at different time points. T1: baseline sample, T2a: after 2 doses of cetuximab and 
before the third dose of cetuximab; T2b: 2 hours after the third dose of cetuximab 
and just before 18FDG-PET (24 hours before surgery); T3: at induction of anesthesia, 
before incision; T4: 5 weeks after surgery. (Representation of the mean and SD for 
each time point, n=14 pts)
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sistent with our previous report based on the ap-
parent diffusion coefficient (ADC) parameter de-
rived from diffusion-weighted magnetic resonance 
imaging (DW-MRI).31 Here, a measure of the mo-
bility of water molecules in tissues, as influenced 
by physiological barriers (endothelium, cell mem-
brane) and obstacles (constituents of the extracel-
lular matrix, intracellular organelles), showed an 
increase in three out of four patients, from a mean 
ADClesion = 1065 mm2.s-1 ± 139 mm2.s-1 to a mean 
ADClesion = 1226 mm2.s-1 ± 209 mm2.s-1 after cetuxi-
mab.23 An example of 18FDG-PET, DCE-CT and 
DW-MRI for one patient before and after treatment 
is illustrated in Figure 4.
Although less investigated and characterized, 
anti-angiogenic properties of cetuximab have also 
been described in vitro. Luwor et al. found a reduc-
tion of hypoxia-inductible factor 1-α (HIF-1α) and 
transcriptional inhibition of vascular endothelial 
growth factor (VEGF) expression in response to 
cetuximab treatment.37 According to previous re-
ports13,14,38, we also observed decreased secretion 
of VEGF, FGF-2 and IL-8 supporting anti-angio-
geneic effects of cetuximab. These modifications 
occurred as early as 2 hours after cetuximab ad-
ministration. However, at the moment of surgery, 
we noticed a significantly increase of these pro-
teins probably induced by the operative stress.39,40 
Furthermore, vascular normalization and normal-
ized tumor oxygenation was observed in xeno-
graft models treated by EGFR-TKIs.15,16 These data 
were not confirmed by the present in vivo study 
which failed to demonstrate a significant change 
in vascularization parameters recorded by DCE 
except for the ve which could be explained by the 
cetuximab-induced cytoreduction, as shown by 
A B C D
E GF H
FIGURE 4. A patient with squamous cell carcinoma of the head and neck. Before cetuximab treatment: (A) PET/CT fusion imaging showing the 
anatomical location of FDG uptake. (B) CT imaging with the regions of interest used for kinetic analysis. (C) ADC mapping derived from DW-MRI with a 
measured ADClesion = 1009 mm2.s-1 ± 123 mm2.s-1. (D) Spin Echo T1-weighted MR imaging with fast suppression technique (SPIR) after gadolinium injection 
(lesion long axis: 2.88 cm, lesion short axis: 1.52 cm). MRI examination was performed 6 days after PET/CT. During treatment with cetuximab: (E) PET/CT 
fusion showing imaging of the decrease of FDG uptake. (F) CT imaging with the regions of interest used for kinetic analysis. (G) ADC mapping derived 
from DW-MRI with an increased ADClesion = 1325 mm2.s-1 ± 192 mm2.s-1 . (H) Spin Echo T1-weighted MR imaging with fast suppression technique (SPIR) after 
gadolinium injection (lesion long axis: 2.72 cm, lesion short axis: 1.12 cm). MRI and CT examinations were performed the same day.
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the decreased tumour cellularity and metabolic 
imaging.
The main limitation of our study was the low 
number of patients assessed by DCE-CT. Statistical 
considerations to determine the number of patients 
to be included in this study were based on 18FDG-
PET responses31 - the DCE-CT analyses were ex-
ploratory and hypotheses generating. However, 
the number of patients was sufficient to observe 
differences in tumor metabolism and extravascu-
lar extracellular space composition induced by the 
therapy but probably insufficient to detect slight 
modifications in tumor vascularization.
Conclusions
To our knowledge, this is the first article to study 
the variation of DCE-CT and 18FDG-PET param-
eters in patients with SCCHN treated with cetuxi-
mab monotherapy. A significant increase in the 
extravascular extracellular space ve, as well as a 
decrease in tumor metabolism by 18FDG-PET, was 
observed. Further investigation in larger cohorts of 
patients is warranted to assess the extent of change 
in perfusion measurements prior to and during 
treatment. Data from such studies could ideally 
translate into values that could predict treatment 
efficacy and provide information on the potential 
effects on tumor blood flow and vascular volume. 
Since only a minority of patients benefit from tar-
geted therapies, identification of early imaging 
markers to predict treatment outcome would be of 
great value to the oncology community.
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